{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:06:51Z","timestamp":1781644011099,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Shanghai Municipality Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clon.2026.104093","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:30:49Z","timestamp":1771605049000},"page":"104093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-0751","authenticated-orcid":false,"given":"J.","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104093_bib1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jtho.2020.01.002","article-title":"Clinicopathologic Characteristics of BRG1-Deficient NSCLC","volume":"15","author":"Dagogo-Jack","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.clon.2026.104093_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.762598","article-title":"A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers","volume":"12","author":"Peng","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.clon.2026.104093_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtho.2023.01.091","article-title":"Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC","volume":"18","author":"Alessi","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.clon.2026.104093_bib4","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.21037\/tlcr-24-381","article-title":"Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer","volume":"13","author":"Long","year":"2024","journal-title":"Translational Lung Cancer Research"},{"key":"10.1016\/j.clon.2026.104093_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19402-8","article-title":"Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients","volume":"11","author":"Fernando","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.clon.2026.104093_bib6","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.clon.2026.104093_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2023.152192","article-title":"The clinicopathological features of BRG1-deficient non-small cell lung cancer and its response to immunotherapy: A single-center retrospective study","volume":"67","author":"Zhang","year":"2023","journal-title":"Annals of Diagnostic Pathology"},{"key":"10.1016\/j.clon.2026.104093_bib8","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.1002\/cam4.6083","article-title":"Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer","volume":"12","author":"Liang","year":"2023","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.clon.2026.104093_bib9","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1007\/s00432-023-04806-y","article-title":"Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor","volume":"149","author":"Lin","year":"2023","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.clon.2026.104093_bib10","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1158\/0008-5472.CAN-14-0061","article-title":"BRG1\/SMARCA4 Inactivation Promotes Non\u2013Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization","volume":"74","author":"Orvis","year":"2014","journal-title":"Cancer Research"},{"key":"10.1016\/j.clon.2026.104093_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2019.10.009","article-title":"Non-small cell lung cancer with loss of expression of the SWI\/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden","volume":"138","author":"Naito","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2026.104093_bib12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/cncy.22581","article-title":"Cytomorphologic features of SMARCA4-deficient non\u2013small cell lung carcinoma and correlation with immunohistochemical and molecular features","volume":"130","author":"Sun","year":"2022","journal-title":"Cancer Cytopathology"},{"key":"10.1016\/j.clon.2026.104093_bib13","article-title":"Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.clon.2026.104093_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107471","article-title":"Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy","volume":"189","author":"Zhou","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2026.104093_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf266","article-title":"Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis","volume":"30","author":"Liu","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.clon.2026.104093_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas","volume":"15","author":"Rekhtman","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.clon.2026.104093_bib17","article-title":"Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor","volume":"12","author":"Zhou","year":"2024","journal-title":"PeerJ"},{"key":"10.1016\/j.clon.2026.104093_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.clon.2026.104093_bib19","article-title":"Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non\u2013Small-Cell Lung Cancer","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.clon.2026.104093_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.clon.2026.104093_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108022","article-title":"Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer","volume":"198","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2026.104093_bib22","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jtho.2020.03.030","article-title":"Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC","volume":"15","author":"Zhou","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.clon.2026.104093_bib23","article-title":"SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy","author":"Wang","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.clon.2026.104093_bib24","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jtho.2021.03.024","article-title":"SMARCA4 and Other SWItch\/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition","volume":"16","author":"Alessi","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.clon.2026.104093_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14070684","article-title":"A Critical Review of the Impact of SMARCA4 Mutations on Survival Outcomes in Non-Small Cell Lung Cancer","volume":"14","author":"Manolakos","year":"2024","journal-title":"Journal of Personalized Medicine"},{"key":"10.1016\/j.clon.2026.104093_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102665","article-title":"Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies","volume":"15","author":"Pan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clon.2026.104093_bib27","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.21037\/tlcr-24-339","article-title":"SWItch\/Sucrose Nonfermentable complex-deficient pulmonary neoplasms: clinicopathologic characteristics and outcomes to radiotherapy and immunotherapy","volume":"13","author":"Gu","year":"2024","journal-title":"Translational Lung Cancer Research"},{"key":"10.1016\/j.clon.2026.104093_bib28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/1878-0261.12831","article-title":"SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis","volume":"15","author":"Liu","year":"2020","journal-title":"Molecular Oncology"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:40:26Z","timestamp":1777592426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"alternative-id":["S0936655526000646"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104093","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104093"}}